“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: Co-inhibition of BRAF and MEK signalling delays progression in BRAF-mutant metastatic melanoma

€2.42

SKU: product-article-11261 Category: General

Description
Reviews (0)

Description

Co-inhibition of BRAF and MEK signalling delays progression in BRAF-mutant metastatic melanoma

Reviews

There are no reviews yet.

Be the first to review “Article: Co-inhibition of BRAF and MEK signalling delays progression in BRAF-mutant metastatic melanoma”

Top

Article: Co-inhibition of BRAF and MEK signalling delays progression in BRAF-mutant metastatic melanoma

Description

Reviews

Related products

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Highlights in urologic cancer

Article: Highlights in respiratory oncology

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer